Capsule formulations containing lanthanum compounds
The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.
1. An oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and talc in an amount from about 0.01% to about 0.05% by weight of the capsule contents, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the talc.
2. The capsule of claim 1 , wherein the shell comprises gelatin.
3. The capsule of claim 2 , wherein the gelatin is in an amount from about 10% to about 95% by weight of the shell.
4. The capsule of claim 1 , wherein after the capsule is stored at 50° C. or 60° C. for 1 or 2 weeks, the lanthanum carbonate or lanthanum carbonate hydrate of the capsule is at least 80% dissolved after 30 minutes in 0.25 M HCl.
5. The capsule of claim 1 , wherein the lanthanum carbonate or lanthanum carbonate hydrate has the formula:
La 2 (CO 3 ) 3 .n H 2 O
wherein n has a value from 0 to 10.
6. The capsule of claim 5 , wherein n has a value from 3 to 6.
7. The capsule of claim 1 , wherein the lanthanum carbonate or lanthanum carbonate hydrate is in an amount from about 50% to about 95% by weight of the capsule contents.
8. The capsule of claim 1 , further comprising a diluent encapsulated in the shell.
9. The capsule of claim 8 , wherein the diluent is dextrates.
10. The capsule of claim 8 , wherein the diluent is in an amount from about 5% to about 50% by weight of the capsule contents.
11. The capsule of claim 1 , further comprising a flow aid encapsulated in the shell.
12. The capsule of claim 11 , wherein the flow aid is colloidal silicon dioxide.
13. The capsule of claim 1 , wherein the flow aid is in an amount from about 0.1% to about 4.0% by weight of the capsule contents.
14. The capsule of claim 1 , further comprising a disintegrant encapsulated in the shell.
15. The capsule of claim 14 , wherein the disintegrant is in an amount from about 1.0% to about 15% by weight of the capsule contents.
16. The capsule of claim 1 comprising (1) 86.7 wt % lanthanum carbonate hydrate, (2) 8.2 wt % dextrates, (3) 1.0 wt % colloidal silicon dioxide, (4) 4.0 wt % crospovidone, and (5) 0.025 wt % talc, wherein the shell encapsulates the lanthanum carbonate hydrate, dextrates, colloidal silicon dioxide, crospovidone, and talc and the weight percentages are based on the weight of the capsule contents.